If comparisons can be odious, so can assumptions.
Jackson
D
D
Duthie
T
T
D000085:Acetates / Q000191:economics* / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003509:Cyclohexanecarboxylic Acids; D004827:Epilepsy / Q000188:drug therapy / Q000191:economics*; D000077206:Gabapentin; D006801:Humans; D000077213:Lamotrigine; D011788:Quality of Life; D016896:Treatment Outcome; D014227:Triazines / Q000191:economics* / Q000627:therapeutic use; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D014227:Triazines; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D020888:Vigabatrin; D000077213:Lamotrigine